Sulcardine administration for treatment of acute atrial fibrillation
Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
1. A method of modulating at least one ECG parameter in a patient suffering from a cardiovascular disease to a non-disease ECG state, wherein said ECG parameter comprise QRS, PDur, PR, QTC, JTpc, and TpTe, the method comprising:
a. administering a pharmaceutical composition comprising a compound, which is N-[4- hydroxy-3,5-bis(1-pyrrolidinylmethyl)benzyl]-4-methoxybenzenesulfonamide or a pharmaceutically acceptable saltthereof;
wherein QRS, PDur, PR, or QTC is increased.
2. The method of claim 1 , wherein JTpc is decreased or unchanged.
3. The method of claim 1 , wherein TpTe is increased or unchanged.
4. The method of claim 1 , wherein said increase in QTc is no more than 40 msec.
5. The method of claim 1 , wherein said method further comprises administering said compound; wherein a plasma concentration of said compound in said patient is about 1,500 ng/mL to about 6,000 ng/mL at about 0.5 hours after administration.
6. The method of claim 5 , wherein said plasma concentration of said compound in said patient decreases by at least 75% within about 1 hour from said administration.
7. The method of claim 1 , wherein the compound is administered to a subject at a dose of from 20 to 1000 mg.
8. The method of claim 5 , wherein said dose is from 150 to 600 mg.
9. The method of claim 1 , wherein said compound is administered over a period of from about 15 minutes to about 2 hours.
10. The method of claim 1 , wherein said pharmaceutically acceptable salt is a sulfate salt.
11. The method of claim 1 , wherein said cardiovascular disease is an AF.
12. The method of claim 11 , wherein said AF is acute AF, paroxysmal AF, or recurrent AF.
13. An improved method of administering a pharmaceutical composition comprising a compound which is N-[4-hydroxy-3,5-bis(1-pyrrolidinylmethyl)benzyl]-4- methoxybenzenesulfonamide or a pharmaceutically acceptable salt thereof, to a patient suffering from a cardiovascular disease, the method comprising:
a. administering said compound at a dose of from 20 to 1000 mg.
wherein a plasma concentration for said compound in said patient is from about 1,200 to about 6,000 ng/mL at about 0.5 hours after administration, and at most 25% of said plasma concentration at about 1.0 hours after said administration.
14. The method of claims 13 , wherein said further comprises modulating one of more ECG parameters to a non-disease state in a patient suffering from a cardiovascular disease, wherein said ECG parameters comprise QRS, PDur, QTc, JTpc, and TpTe.
15. The method of claim 14 , wherein QRS, PDur, PR, or QTc is increased.
16. The method of claim 14 , wherein JTpc is decreased or unchanged.
17. The method of claim 14 , wherein TpTe is increased or unchanged.
18. The method of claim 14 , wherein said increase in QTc is no more than about 40 msec.
19. The method of claim 13 , wherein said compound is administered over a period of from about 15 minutes to about 2 hours.
20. The method of claim 13 , wherein said pharmaceutically acceptable salt is a sulfate salt.
21. The method of claim 14 , wherein said cardiovascular disease is AF.
22. The method of claim 21 , wherein said AF is acute AF, paroxysmal AF, or recurrent AF.